Clostridioides difficile Infection in the Stem Cell Transplant and Hematologic Malignancy Population - 18/04/19
, Nasia Safdar, MD, PhD a, bRésumé |
Clostridioides difficile infection (CDI) is common in the stem cell transplant (SCT) and hematologic malignancy (HM) population and mostly occurs in the early posttransplant period. Treatment of CDI in SCT/HM is the same as for the general population, with the exception that fecal microbiota transplant (FMT) has not been widely adopted because of safety concerns. Several case reports, small series, and retrospective studies have shown that FMT is effective and safe. A randomized controlled trial of FMT for prophylaxis of CDI in SCT patients is underway. In addition, an abundance of novel therapeutics for CDI is currently in development.
Le texte complet de cet article est disponible en PDF.Keywords : Stem cell transplant, Hematologic malignancy, Clostridioides (Clostridium) difficile, Graft-versus-host disease
Plan
| Disclosure: The authors report no conflicts of interests. Nasia Safdar receives grant support from the National Institutes of Health (DP2AI44-244 and U01AI125053) and Agency for Healthcare Research and Quality (R01HS026226 and R01HS025713). |
Vol 33 - N° 2
P. 447-466 - juin 2019 Retour au numéro
Article précédent
- Bacterial Infections in the Stem Cell Transplant Recipient and Hematologic Malignancy Patient
- Elizabeth Ann Misch, David R. Andes
- Herpes Virus Infections Other than Cytomegalovirus in the Recipients of Hematopoietic Stem Cell Transplantation
- Sanjeet Singh Dadwal
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?